correction: gdp versus eshap regimen in relapsed and/or refractory hodgkin lymphoma: a comparison study

gdp versus eshap regimen in relapsed and/or refractory hodgkin lymphoma: a comparison study.

despite multiple published studies reporting result of salvage regimens for relapsed and refractory hodgkin's lymphoma, there are no comparisons of different combinations.a total of 44 patients identified with refractory or relapsed hodgkin's lymphoma were considered eligible for this study. the patients were randomly divided into two groups of 22, one of which were treated with gdp regimen (ge...

GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study

BACKGROUND Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different combinations. PATIENTS AND METHODS A Total of 44 patients identified with refractory or relapsed Hodgkin's Lymphoma were considered eligible for this study. The Patients were randomly divided into two groups of 22, one of whic...

Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran

BACKGROUND Chemotherapy for lymph nodes cancer is often composed of several drugs that are used in a treatment program. OBJECTIVES The aim of this study was to perform a cost-utility analysis of IEV regimen (ifosfamide, epirubicin and etoposide) versus ESHAP regimen (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin) in patients with lymphoma in the south of Iran. PATIENTS ...

iev (ifosfamide, epirubicin, vp16) regimen as salvage therapy for early relapsed/refractory non-hodgkin/hodgkin lymphoma

introduction: management of early relapsed or refractory lymphoma [hodgkin & non- hodgkin lymphoma (hl & nhl)] is a matter of problem, especially when hematopietic stem cell support is not available. the aim of this study was to evaluate effectiveness of iev regimen ( ifosfamide, epirubicin, vp16), in lymphoma patients who are not candidate for stem cell transplantation. because the majority of...

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.

The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma (NHL) in therapeutic trials. We undertook this study to determine whether this regimen would be effective and tolerable in Korean patients. A total of 40 patients ...

Treatment of relapsed/refractory Hodgkin lymphoma.